To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: Temozolomide Not Superior to Procarbazine-Based Combination Treatment in Patients With High-Grade Glioma: Presented at ESMO URL: http://www.pslgroup.com/dg/22CBF6.htm Doctor's Guide September 18, 2008
By Ed Susman STOCKHOLM, Sweden -- September 18, 2008 -- Treating patients with temozolomide monotherapy is not more effective than the standard therapy of procarbazine, lomustine, and vincristine (PCV) in a clinical trial involving patients with high-grade gliomas, according to a study presented here at the 33rd European Society for Medical Oncology Congress (ESMO). Patients in the study who were assigned to temozolomide achieved 7.2 months of progression-free survival compared with 6.7 months among patients assigned to the PCV regimen, a 9% decreased risk of disease progression. Ming Lee, MD, University College Hospitals, London, United Kingdom, presented the study results during the late-breaker symposium on September 15. Median time to progression was 4.7 months in the temozolomide patients and 3.6 months in the PCV patients, a nonsignificant difference (P = .23) for the secondary endpoint outcome. Dr. Lee and colleagues also subdivided the temozolomide patients into 2 groups: a 5-day treatment of 200 mg/m2 every 28 days or a 21-day treatment of 100 mg/m2 in a 28-day cycle. Patients were given a maximum of 9 cycles or until disease progression occurred. After 12 weeks, 63.6% of patients receiving the 5-day treatment exhibited no signs of progression compared with 65.7% the patients on the 21-day treatment with temozolomide, again showing no significant difference (P = .75). However, there was a difference in progression-free survival among the 5-day temozolomide patients and those getting the longer treatment. Dr. Lee said patients on the shorter therapy had a 5-month progression-free survival compared with a median of 4.2 months for those patients on the prolonged treatment (P = .02). There was also a strong trend (P = .06) for a longer survival among patients who received the 5-day treatment (8.5 months) compared with 6.8 months for patients on the 21-day regimen. "Temozolomide-5 was superior to temozolomide-21 schedule with respect to progression-free survival and overall survival," Dr. Lee said. "These results question the current basis of increasing temozolomide dose intensity by prolonging scheduling." [Presentation title: A Randomised Trial of Procarbazine, CCNU and Vincristine (PCV) vs Temozolomide (5-Day or 21-Day Schedule) for Recurrent High Grade Glioma (MRC BR12, ISRCTN83176944). LBA5] --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.